Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of cognitive impairment, with a notably higher likelihood of developing non-amnestic mild cognitive impairment.
Neuropsychological assessment, or cognitive testing, is the gold standard tool for measuring cognitive functions (or the “software” of the brain) such as memory, language, attention, visuospatial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback